U.S. Markets open in 5 hrs

Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that Asa Abeliovich, M.D., Ph.D., Founder and CEO, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 10:20 a.m. ET in New York City.

The live webcast will be available in the investor section of the company's website at www.prevailtherapeutics.com. The webcast will be archived for 90 days following the presentation.

About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for PR001 to transform the lives of patients with Parkinson’s disease; the timing of initiation of Prevail’s Phase 1/2 clinical trial of PR001; and the potential advantages of FDA’s Fast track designation. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others:  our novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; PR001 may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; and the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change. These and other risks are described more fully in Prevail’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Katie Engleman
1AB
katie@1ABmedia.com

Investor Contact:
investors@prevailtherapeutics.com